Qiagen (QGEN) has released an update.
Qiagen has announced the discontinuation of its NeuMoDx PCR testing systems due to post-pandemic market shifts, while also updating its full-year 2024 earnings outlook to a higher adjusted diluted EPS of $2.14 CER. The company plans to take a restructuring charge of approximately $400 million, primarily in Q2 2024, but ensures continued support for existing NeuMoDx customers during the transition. Qiagen reaffirms its commitment to profitability and investment in other innovative areas of its portfolio.
For further insights into QGEN stock, check out TipRanks’ Stock Analysis page.
